Ask Warren

LigaChem Biosciences

141080 · KOSDAQ · ₩141080 · 리가켐바이오

₩61,500▼ ₩2,500 (3.91%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩5.5B₩36B₩16B₩41B₩33B₩52B₩34B₩30B
Cost of sales₩2.4B₩2.3B₩3.7B₩3.8B₩4.1B₩4B₩4.3B₩3.7B
Gross profit₩3.2B₩34B₩12B₩38B₩29B₩48B₩29B₩27B
Operating income−₩72B−₩37B−₩73B−₩23B−₩22B₩11B−₩14B₩517M
Net income−₩68B−₩33B−₩65B−₩15B−₩38B₩26B−₩5.4B₩11B
Net income to shareholders−₩68B−₩33B−₩65B−₩15B−₩38B₩26B−₩5.4B₩11B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩594B₩653B₩702B₩699B₩704B₩740B₩738B₩727B
Current assets₩426B₩480B₩521B₩596B₩623B₩539B₩550B₩562B
Cash and equivalents₩84B₩63B₩99B₩153B₩136B₩108B₩129B₩154B
Total liabilities₩153B₩152B₩161B₩136B₩152B₩170B₩122B₩90B
Current liabilities₩45B₩47B₩61B₩66B₩82B₩101B₩117B₩83B
Borrowings₩94B₩95B₩0₩84B₩85B₩98B₩0₩12B
Total equity₩441B₩501B₩541B₩563B₩552B₩569B₩616B₩637B
Shareholders' equity₩400B₩463B₩508B₩554B₩571B₩583B₩616B₩637B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩60B−₩47B−₩73B−₩12B−₩8.4B−₩31B₩15B−₩23B
Capital spending₩1.3B₩344M₩935M₩418M₩1.4B₩281M₩564M₩823M
Free cash flow−₩61B−₩47B−₩74B−₩13B−₩9.8B−₩31B₩14B−₩23B

Consolidated where available. Amounts in won.

Also known as: LigaChem Biosciences / 리가켐바이오 / 141080 / KRX:141080

Source: KRX statistical information